Evommune, Inc.

Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. Its initial clinical programs target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The company's lead product candidate, EVO756, is being developed for the treatment of CSU and AD. Another candidate, EVO301, targets AD and UC. Evommune aims to address key drivers of inflammation in these conditions, offering potential new treatment options for patients.

Evommune, Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol EVMN. The company's stock trades in US Dollars (USD), reflecting its primary listing in the United States. As a US-based company, its financial reporting and market transactions are conducted in USD.

Evommune operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies for diseases, particularly chronic inflammatory conditions. The company's work involves advanced biological and molecular approaches to create treatments that target specific disease pathways.

Evommune, Inc. is headquartered in Palo Alto, California, United States. The company was incorporated in 2020, making it a relatively young player in the biotechnology field. Its location in Palo Alto places it within a major hub for biotechnology and innovation, providing access to talent, research collaborations, and the broader life sciences ecosystem.

Evommune's pipeline includes two main product candidates. EVO756 is being developed for chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), both chronic inflammatory skin conditions. EVO301 targets atopic dermatitis (AD) and ulcerative colitis (UC), an inflammatory bowel disease. These candidates are in clinical-stage development, meaning they are being tested in human trials to evaluate safety and efficacy. The company's focus on these indications addresses significant unmet medical needs in inflammatory diseases.